Fielder Capital Group LLC Acquires New Holdings in Zoetis Inc. (NYSE:ZTS)

Fielder Capital Group LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,945 shares of the company's stock, valued at approximately $480,000.

Several other institutional investors have also bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter worth about $31,000. First Personal Financial Services acquired a new stake in Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Finally, Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Stock Down 0.4 %

Zoetis stock traded down $0.75 during mid-day trading on Tuesday, hitting $169.79. The company's stock had a trading volume of 3,006,973 shares, compared to its average volume of 3,255,321. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company has a market cap of $76.03 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm's 50 day moving average is $166.42 and its 200 day moving average is $177.16.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and an average target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.